CXCR2 and rheumatoid arthritis: Preclinical studies suggest that CXCR2 antagonists (e.g., navarixin), currently in Phase II trials for rheumatoid arthritis (NCT04000789), could be repurposed for OA patients with predominant inflammatory phenotypes.